Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de serina y fenofibrato en pacientes con MacTel tipo 2 (SAFE)

25 de agosto de 2026 actualizado por: The Lowy Medical Research Institute Limited

Estudio de fase 2a sobre el efecto de la suplementación con serina y el tratamiento con fenofibrato en los niveles séricos de desoxiesfinganina en pacientes con telangiectasia macular (MacTel) tipo 2 (estudio SAFE)

This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Additional Procedures include:

  1. Fasting blood work
  2. Collection of microbiome samples

Tipo de estudio

Intervencionista

Inscripción (Actual)

89

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48105
        • Kellogg Eye Center, University of Michigan
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44122
        • Retina Associates of Cleveland
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37922
        • Southeastern Retina Associates
    • Texas
      • Bellaire, Texas, Estados Unidos, 77401
        • Retina Consultants of Texas
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84132
        • Moran Eye Center, University of Utah
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • University of Washington
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • The Eye Institute, Medical College of Wisconsin
      • London, Reino Unido, ECV2PD
        • Moorfields Eye Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
  2. Males/females 21 years of age or older;
  3. English speaking;
  4. Enrolled in the Natural History Observation and Registry Study (NHOR) and diagnosed with confirmed MacTel type 2 in at least one eye;
  5. Willing to use contraception, if applicable; and
  6. Willing to comply with study protocol and follow-up visits.

Exclusion Criteria:

  1. Participant is unable to provide informed consent;
  2. Participant is less than 21 years of age;
  3. Participant is currently taking, or has taken within four weeks prior to screening, a serine or glycine supplement;
  4. Participant is currently taking, or has taken within 12 months prior to screening, fibrates including clofibrate, ciprofibrate, bezafibrate, fenofibrate, and gemfibrozil;
  5. Participant is currently taking an anticoagulant, colchicine, cyclosporine, tacrolimus or bile acid binding resins;
  6. Participant has known allergy to fibrates and/or serine;
  7. Participant has a known history of clinically significant myopathy or myalgia related to cholesterol-lowering drugs;
  8. Participant has active liver disease and/or elevated liver enzymes*;
  9. Participant has renal dysfunction as evidenced by elevated serum creatinine* and/ or glomerular filtration rate (GFR) less than 90 mL/min;
  10. Participant has thrombocytopenia as evidenced by a platelet count below 100,000 per microliter, anemia as evidenced by hemoglobin levels below 10 g/dL, or history of bleeding disorder;
  11. Participant has a history of gallbladder disease or has had a cholecystectomy;
  12. Participant has triglyceride levels greater than 400 mg/dL on treatment, or greater than 700 mg/dL on no treatment;
  13. Participant has untreated/uncured Hepatitis C, or a history of Hepatitis B, autoimmune hepatitis, or HIV;
  14. Participant has had any malignancies within the last 5 years (not including basal cell carcinoma);
  15. Participant has ever been enrolled in a clinical trial involving ciliary neurotrophic factor (CNTF) treatment;
  16. Participant is currently enrolled in another clinical trial that involves treatment or participated in one within the last 30 days;
  17. Participant is pregnant, breastfeeding or planning a pregnancy;
  18. Participant is medically unable to comply with study procedures or follow-up visits;
  19. Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments; or
  20. Patient is unavailable for follow-up visits. *based on reference range for the local laboratory used

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Serine 200 mg/kg/day

Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Experimental: Serine 400 mg/kg/day

Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Experimental: Fenofibrate 160 mg/day

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Fenofibrate 160mg pill, taken orally

Experimental: Serine 200 mg/kg/day and Fenofibrate 160 mg/day

Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Fenofibrate 160mg pill, taken orally

Experimental: Serine 400 mg/kg/day and Fenofibrate 160 mg/day

Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).

Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Fenofibrate 160mg pill, taken orally

Sin intervención: No treatment

Control group: no investigational product taken

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety Assessment
Periodo de tiempo: Reported over the10 weeks from baseline to exit visit

Safety assessment measured via examined AEs and SAEs (during study visits) and via participant self-reported AEs and SAEs that occurred between visits

Reported over the10 weeks from baseline to exit visit
Percentage Change of Serum Deoxysphingolipid Levels From Baseline to 6 Weeks
Periodo de tiempo: Blood draw at baseline and 6 weeks on product

Percentage change in the sum of 7 different deoxy-dihydroceramides species detected. Negative values mean these metabolites decreased during the treatment period. Deoxy-sphingolipids were measured in serum using LC-MS.

Blood draw at baseline and 6 weeks on product

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage Change in Serum Lipid Levels From Baseline to 6 Weeks
Periodo de tiempo: blood draws from baseline and week 6 on product

Percent changes in lipid levels measured between baseline and 6 weeks. These lipid levels were obtained from the local clinical lab at each site as part of a lipid panel. Negative values mean these metabolites decreased during the treatment period.

blood draws from baseline and week 6 on product
Percentage Change in Serum Serine and Glycine Levels From Baseline to 6 Weeks
Periodo de tiempo: blood draws from baseline and week 6 on product

Percentage change in fasting levels of the two amino acids serine and glycine. Serine supplementation is part of the treatment and glycine can be produced from serine by different cells in the body. Serine and glycine levels were measured from serum using LC-MS.

blood draws from baseline and week 6 on product

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Mari A Gantner, PhD, Lowy Medical Research Institute

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de abril de 2022

Finalización primaria (Actual)

30 de septiembre de 2024

Finalización del estudio (Actual)

30 de septiembre de 2024

Fechas de registro del estudio

Enviado por primera vez

25 de mayo de 2021

Primero enviado que cumplió con los criterios de control de calidad

25 de mayo de 2021

Publicado por primera vez (Actual)

28 de mayo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir